

Sir,
Calcification of Rayner hydrophilic acrylic intra-ocular lenses after Descemet's stripping automated endothelial keratoplasty

Calcification of an intra-ocular lens (IOL) is an infrequent but clinically significant event. We report four cases of late calcification of Rayner (Hove, UK) hydrophilic acrylic intra-ocular lenses (HA-IOLs) after Descemet's stripping automated endothelial keratoplasty (DSAEK).

Case details are outlined in Table 1. All patients were pseudophakic with clear IOLs before DSAEK surgery. Opacification over the centre of the optic occurred between 7 and 26 months post DSAEK, necessitating IOL exchange. Ultrastructural analysis on three explanted lenses with Alizarin red staining, X-ray spectroscopy, and scanning electron microscopy confirmed calcification as the cause (Figure 1).

Our case series adds to the growing body of evidence that HA-IOLs in general are at risk of calcification post DSAEK. Besides Rayner, reports have recently implicated

Akreos Adapt¹ (Bausch and Lomb Inc., Rochester, NY, USA), Memory Lens² (Ciba Vision, Duluth, GA, USA), EasyCare600² (Tekia Inc., Irvine, CA, USA), 47c² (Acimed, now Oculentis, Berlin, Germany), and CF Acrylic lenses² (Humanoptics, Erlangen, Germany) in post-DSAEK calcification.

All of our patients required repeat injection of intra-cameral air to achieve graft attachment ('re-bubbling'), which is a consistent risk factor across these reports. Isolated cases of HA-IOL calcification in non-DSAEK patients where intra-cameral gas was used for other indications—such as C₃F₈ and SF₆ for a Descemet's tear³ and SF₆ for ocular hypotony¹—support the role of intra-cameral gas in the pathogenesis of HA-IOL calcification.

We propose that the trauma of repeat surgery involved in re-bubbling may disrupt the blood–aqueous barrier, increasing the concentration of calcium ions. The consistent finding of calcification restricted to the central part of the optic not protected by iris, suggests that the gas bubble in physical contact with the IOL surface is an important biochemical trigger for calcification.

We have never encountered HA-IOL calcification in patients after routine cataract surgery or after DSAEK

Table 1 Details of four cases with intra-ocular lens calcification

#	Age, Ind	PMHx	Ocular IOL	comor	DSEK	Re-bub	Other events	Summary pre-haze	Outcome
1	92	FED T2DM, IHD	None	Superflex 620H Aug 2007 Routine phaco	DSEK	Yes Feb 18 2011 days	No	Graft re-bubbled × 1. Haze at 7 months post DSEK	IOL exchange with anterior vitrectomy and ACIOL (16 months post DSEK, May 2012). VA improved from 6/18 before exchange to 6/12 at last review (25 months post DSEK, March 2013)
2	82	FED HTN	None	Centerflex 570H Apr 2002 Routine phaco	DSEK	Yes Nov 19 2009 days	Rejection	Graft re-bubbled × 1. Graft rejection. IOL haze noted at 20 months post DSEK	IOL exchange with anterior vitrectomy and ACIOL (32 months post DSEK, July 2012). Post-operative graft failure. Graft re-done as a penetrating keratoplasty (39 months post DSEK, March 2013). Last VA 6/36 in June 2013
3	79	FED HTN, Breast cancer	None	C-flex 970C Dec 2011 Routine phaco	DSEK	Yes Apr 10 2012 days	No	Graft re-bubbled × 1. Haze at 5 months post DSEK	IOL exchange with anterior vitrectomy and ACIOL (10 months post DSEK, Feb 2013). Post-operative graft failure, graft re-done as a penetrating keratoplasty (15 months post DSEK, July 2013). Last VA 6/60 in July 2013
4	78	FED Parkinson's RD	repair	Superflex 620H Mar 2009 Routine phaco	DSEK	Yes Aug 0 day 2009 and 4 days	Redid DSEK	First DSEK re-bubbled × 2. DSEK repeated Oct 2010. Haze 12 months after second DSEK (26 months after first DSEK)	IOL exchange with anterior vitrectomy and ACIOL (17 months after second DSEK, March 2012). VA improved from 6/18 with haze to 6/6 unaided at last review (28 months after second DSEK, Feb 2013)

Abbreviations: ACIOL, anterior chamber intra-ocular lens; DSEK, Descemet's stripping endothelial keratoplasty; FED, Fuchs' endothelial dystrophy; HTN, hypertension; IHD, ischaemic heart disease; IOL, intra-ocular lens; Ind, indication; ocular comor, ocular co-morbidity of operated eye; PMHx, past medical history; re-bub, re-bubbled; T2DM, type 2 diabetes mellitus; VA, visual acuity.




Figure 1 (a) Opacification of the IOL optic in Case 1, (b) scanning electron microscopy (SEM) cross-section demonstrating calcium crystals within the IOL optic just below the surface and (c) SEM of the IOL surface showing discrete elevations associated with sub-surface deposition of crystals leading to focal disruption of the anterior lens surface in places.

with only one bubble of air. However, an institutional audit identified 10 patients with a Rayner HA-IOL who required a re-bubble after DSAEK. That four of these (all described in this report) developed subsequent lens calcification suggests a significant risk. We now use hydrophobic IOLs in patients with corneal pathology who may require DSAEK in future, given that IOLs with lower water content are less prone to calcification.^{4,5}

Conflict of interest

The authors declare no conflict of interest.

Acknowledgements

We thank Professor Gerd U Auffarth from Heidelberg University for his help with the analyses of the explanted lenses and Dr Duncan Leadbetter for help with data collection.

References

- 1 Dhital A, Spalton DJ, Goyal S, Werner L. Calcification in hydrophilic intraocular lenses associated with injection of intraocular gas. *Am J Ophthalmol* 2012; **153**(6): 1154–1160.
- 2 Neuhann IM, Neuhann TF, Rohrback JM. Intraocular lens calcification after keratoplasty. *Cornea* 2013; **32**(4): e6–e10.
- 3 Saeed MU, Singh AJ, Morrell AJ. Sequential Descemet's membrane detachments and intraocular lens haze secondary to SF₆ or C₃F₈. *Eur J Ophthalmol* 2006; **16**: 758–760.
- 4 Gartaganis SP, Kanellopoulou DG, Mela EK, Panteli VS, Koutsoukos PG. Opacification of hydrophilic acrylic intraocular lens attributable to calcification: investigation on mechanism. *Am J Ophthalmol* 2008; **146**: 395–403.
- 5 Nakanome S, Watanabe H, Tanaka K, Tochikubo T. Calcification of Hydroview H60M intraocular lenses: aqueous humor analysis and comparisons with other intraocular lens materials. *J Cataract Refract Surg* 2008; **34**: 80–86.

R De Cock and MAP Fajgenbaum

Kent and Canterbury Hospital, East Kent Hospitals University Trust, Canterbury, UK
E-mail: romain.d@btinternet.com
Presentations: This work was presented at the European Society of Cataract and Refractive Surgeons (ESCRS) conference, Amsterdam, Holland, October 2013.

Eye (2014) **28**, 1383–1384; doi:10.1038/eye.2014.175;
published online 1 August 2014

Sir, Urrets – Zavalía syndrome as a complication of ocular hypotonia due to intravenous cidofovir treatment

We read the article written by Orssaud *et al*¹ published in your valuable journal. They reported a case of Urrets–Zavalía syndrome (UZS) after receiving intravenous cidofovir treatment for laryngotracheal papillomatosis. They reported that anterior uveitis was observed in both eyes and the authors prescribed topical steroid and topical atropine 1% twice a day. Despite discontinuation of topical atropine therapy, she developed UZS in the left eye. They related the fixed dilated pupil to ocular hypotonia. However, they used atropine for the treatment of anterior uveitis and the iatrogenic mydriasis is a more common reason for the UZS as described by Mocan *et al*² (although the other eye did not develop UZS). As they proposed, iris ischemia precipitated by iris dilation and strangulation of iris vessel and iatrogenic damage to the radial nerve fibers of the iris could result in UZS.

Conflict of interest

The authors declare no conflict of interest.

References

- 1 Orssaud C, Wermert D, Roux A, Laccourreye O, Sors H, Roche O *et al*. Urrets-Zavalía syndrome as a complication of ocular hypotonia due to intravenous cidofovir treatment. *Eye* 2014; **28**: 776–777.
- 2 Mocan MC, Bozkurt B, Irkec M. Urrets-Zavalía syndrome following iatrogenic pupil dilation in eyes with pigment dispersion. *Can J Ophthalmol* 2009; **44**(2): 216–217.

M Soleimani, SA Tabatabaei and S Moghimi

Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran
E-mail: Soleimani_md@yahoo.com

Eye (2014) **28**, 1384; doi:10.1038/eye.2014.166; published online 25 July 2014